Company

Lin BioScience, Inc.

Headquarters: Taipei, Taiwan

CEO: Dr. Yuxin Lin M.B.A., Ph.D.

TWSE: 6696 +1.97%

Market Cap

TW$7.23 Billion

TWD as of July 1, 2024

US$222.2 Million

Market Cap History

Lin BioScience, Inc. market capitalization over time

Evolution of Lin BioScience, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Lin BioScience, Inc.

Detailed Description

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (AMD) and stargardt diseases; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei City, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Lin BioScience, Inc. has the following listings and related stock indices.


Stock: TWSE: 6696 wb_incandescent

Stock: MYX: 5789 wb_incandescent

Details

Headquarters:

No. 68, Zhongxiao East Road

12th Floor, Sec 5 Xinyi District

Taipei, 110

Taiwan